Amgen

Amgen: Unlocking the Potential of Biology for Patients

Amgen is a leading biotechnology company that has been at the forefront of developing innovative human therapeutics for over 40 years. The company's mission is to unlock the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering life-changing medicines.

Founded in 1980 by William K. Bowes Jr., Amgen has grown to become one of the largest biotech companies in the world with a presence in more than 100 countries. The company's headquarters are located in Thousand Oaks, California, and it employs over 23,000 people globally.

Amgen's focus on innovation and patient-centricity has led to numerous breakthroughs in medicine. The company has developed several blockbuster drugs that have transformed the lives of millions of patients worldwide. Some notable examples include Enbrel (etanercept) for rheumatoid arthritis and other autoimmune diseases; Neulasta (pegfilgrastim) for chemotherapy-induced neutropenia; Prolia (denosumab) for osteoporosis; and Repatha (evolocumab) for high cholesterol.

In addition to its commercial success, Amgen is also committed to advancing scientific research and education. The company invests heavily in R&D activities aimed at discovering new treatments for unmet medical needs. It also supports various educational initiatives designed to inspire future generations of scientists and healthcare professionals.

One area where Amgen is particularly active is oncology research. Cancer remains one of the most challenging diseases facing humanity today, with millions of people diagnosed each year worldwide. Amgen's oncology portfolio includes several promising drugs that target different types of cancer cells using innovative mechanisms.

For example, Blincyto (blinatumomab) is a bispecific T-cell engager antibody that helps activate T-cells against cancer cells expressing CD19 antigens found on B-cell malignancies such as acute lymphoblastic leukemia (ALL). Another drug called Kyprolis (carfilzomib) targets proteasomes within cancer cells responsible for breaking down proteins needed by tumor cells to grow uncontrollably.

Apart from oncology research, Amgen also focuses on other therapeutic areas such as cardiovascular disease, neuroscience disorders like Alzheimer’s disease or migraine headaches among others which are some major health challenges faced by society today.

To achieve its mission successfully while maintaining high ethical standards across all aspects including clinical trials or marketing practices - Amgen operates under strict regulatory guidelines set forth by various government agencies around the world including FDA(US), EMA(Europe), PMDA(Japan), etc., ensuring safety & efficacy data before launching any new product into marketplaces globally.

Conclusion:

In conclusion, Amgen stands out as an industry leader when it comes to unlocking biology’s potential through innovative human therapeutics development & delivery systems while maintaining high ethical standards across all aspects including clinical trials or marketing practices - making them an ideal partner choice if you're looking forward towards improving your health outcomes!